making that growing revenue Thanks, this I thanks while a everyone quarter joining is today's on basis. Jen. successfully our challenging We're with this highlight the reduced the company want consecutive Welcome environment, pleased to is the and we've for that maintained expenses operating progress call. and in fourth or year-over-year
former strengthened ThermoFisher. market, of new making additional we of through to with the and revenue kits which results, As strategic quarter's Paul addition installed both of Directors continue progress and BioXp you'll in Board secured Meister, the delivered see this Chairman the financing, our grew our base, collaborations,
SOLA, platform our we technical look we during by enzymatic validate made research this I'm our continuing the encouraged forward the in partner. that validates progress DNA with something Pfizer, second announce our also that platform. synthesis to remain achieved further to pleased We another quarter collaboration with have milestone to and
SOLA workflows accelerate will shop drive production synthesis, deliver through remains integrated continue speed that to timelines gene a with discovery our to of eventually products bench customers the on-demand accuracy. will and and ability mRNA to for disruptive protein synthesis technology unprecedented and the
our we increasingly encouraging, efforts impact products BioXp remains of DNA of intend maximizing adoption differentiated based mRNA, newly to the forward on scale-up focus on long-build moving cell-free and Customer our and our workflow solutions DNA kits. our launched commercial
solutions, and pathway products targeted have of We highly the mRNA which medicine, compelling adoption our a benchtop these engineering, discovery. catalyze precision into vaccine offering discovery, antibody for our further at for will workflows
quarter Now, to moving second on our financial results.
Our in detailed the release. quarter press included second financial for results are today's
During our XX% revenue the despite headwinds product that at results. continued impacted total grew our quarter, macroeconomic revenue
XXXX. the half XXXX, We this saw new revenue by the product noted accelerate end that solid kit a comp very and our XX%, was is we of kit growth year-over-year revenue year XX% BioXp revenue launches. down will rate in instrument anticipate that than for greater BioXp While first increased overall growth of in and tough our with in the the business of we product the our XX% during XX%, quarter against
period XXXX. period in to for XX% million second the were year to Revenue $XX.X period. the and in the in first the XX.X% XX.X% prior was of XX% of the prior $XX XXXX margins from compared Gross of the and compared first million, for quarter the an the in of increase half came prior XX.X% half XXXX for as at same for
to portfolio our reagent our collaboration continued launched and Strong contributors manufacturing. to expansion this efforts vertically recently but reflect within growing revenue positive also milestones, mix in and from include integrate shift BioXp instrument products
the current XX% in quarter ongoing the of as a result period same quarter reduction the down efforts, second in expenses a down million cost-cutting compared primarily for to to This revenue is million were for first in team intended near-term quarter of to XXXX the for half force decrease profitable operating during the million that for for XX% focus XXXX. the was year. including prior $XX.X $XX.X $XX.X same the on of were And $XX.X expenses most compared million Operating to the opportunities. period our and
was $XX.X reflects loss Total same prior net in XX% million the loss the in compared XXXX, first half period for of million per the of compared the to and XXXX of quarter to and in $X.XX second of as XX% short-term of equivalents, XXXX. $XX.X million corresponding year representing cash, restricted loss XXXX period. $X.X net XX, $XX share the a a of million June cash million the The for investments net decrease. a $X.XX decrease for for loss to net year period compared $XX.X were was prior corresponding same Cash,
and And status. commercial to with I'll a that, move brief our provide development on update product on
the accomplished development launch of kits, including kits bringing to During total XXXX the product BioXp XXXX on-time important and new QX systems. several initiatives, both our XX we offering three across
the enables the existing automated linear shipment of DNA. assembly DNA benchtop cloning our on-demand Cloning BioXp fragments via an or Golden Gate customer’s completed assembly of methods Gibson beginning DNA first method own and we note, Of assembly our Select commercial from Kit, proprietary which
in systems. And benchtop to to Telesis appeal so, the that product used doing Cloning Gate commonly have the at are methodologies. cloning on and automated customers Golden kits for now perform are methods Bio the two This by workflows, cloning most now broadens their these and both customers launch available used our XXXX able XXXX
in for NGS BioXp next-gen and preparation sequencing library kit on-demand biology for and solution many Second, workflows. DNA milestone automated we synthetic of launched evolution This use system now a enables kit represents genomics more across a the applications. plasma BioXp with major of proprietary provides in Plasmid which Library complete customers Prep the Sequencing, our and
single, rapid by to to run. Synthesis overnight now genes This in in XX third, advancement by adoption are key up genes, launch And the precision introduced on and a this being the fully discovery. medicine the which a we're high-fidelity kits automated for able customers we build is long with of With longer pleased launch, vaccine in kb and Template DNA fragment system. Synthesis customers mRNA driven are XXXX initial for product numbers, X.X Automation
focused products workflows remain the complex increase to and here of the optimize on adoption value where will an serve move into at in we that have differentiated discovery Telesis platform. of targeted team these we growth through accelerate as in early benchtop. the to deeper expect We biology disruptive that in The range to stages technology of accelerate BioXp expanded remains and of at researchers delivering differentiated proposition workflows our push-button products automation the enable molecular
result gross of kits shift Moving expand. the like to on BioXp. which to as of XXXX expand a for to margin, the to suite margin system, continue products and kits, select margins mixed continues mRNA long builds, Gross higher fragment a
the briefly initiatives We our full of activities of to initiative XXXX. This, a year few the to instruments, when taking commitment anticipate margin related accrete BioXp combined manufacturing supply these effect to the that with we substantially to manufacturing three likewise offset gross with vertically end to of external in mentioned gross should the existing continue place we vertical our minutes margins integration will with XXXX. integrate as oligo ago complete improve by
status our on the base And finally, structure. a of cost comment brief
revenue we is the maintained a call, in As environment, pleased year-over-year fourth highlight on in progress to this making consecutive are want growing this and earlier the with company successfully expenses, again is while mentioned quarter operating we or the that have challenging basis. the I reduced
the As of such, our track. end continue be path XXXX, that to remains on we remain profitability, to estimated confident to
our goals, existing closing, want new controlling In profit furthering we new and achieving experienced is partnerships, costs, to I strategically, launching commercial team that operationally, and share and very on near-term focused products, remain improving that margins. strong
the that, the with to open operator questions. ask for And call you. I'll Thank
